Methylphenidate derivatives and uses of them
| Title: | Methylphenidate derivatives and uses of them |
|---|---|
| Patent Number: | 9,463,187 |
| Publication Date: | October 11, 2016 |
| Appl. No: | 13/288179 |
| Application Filed: | November 03, 2011 |
| Abstract: | The present invention provides methods of using compounds of formula I: [chemical expression included] and salts and prodrugs thereof, wherein n, R1 and R2 are defined herein. The invention also provides certain novel compounds of formula I and pharmaceutical compositions comprising them. |
| Inventors: | Bar-Or, David (Englewood, CO, US); Rao, Nagaraja K. R. (Cardiff, GB) |
| Assignees: | Ampio Pharmaceuticals, Inc. (Englewood, CO, US) |
| Claim: | 1. A method of inhibiting the proliferation of a breast cancer cell, comprising contacting the cell with an effective amount of a compound of formula I: [chemical expression included] or a salt thereof, where n is 1, R1 is phenoxy, and wherein R 2 is hydrogen or lower alkyl. |
| Claim: | 2. The method of claim 1 , wherein the breast cancer cell is a carcinoma cell. |
| Claim: | 3. The method of claim 1 , wherein the compound has the structure: [chemical expression included] |
| Patent References Cited: | 2507631 May 1950 Hartmann et al. 2957880 October 1960 Rometsch et al. 5407926 April 1995 Clark 5658955 August 1997 Hitzig 5859249 January 1999 Seido et al. 5908850 June 1999 Zeitlin et al. 6025502 February 2000 Winklter et al. 6060463 May 2000 Freeman 6127385 October 2000 Midha et al. 6210705 April 2001 Mantelle et al. 6395752 May 2002 Midha et al. 6486177 November 2002 Zeldis et al. 6555543 April 2003 Bar-Or et al. 7267949 September 2007 Richards et al. 8076485 December 2011 Bar-Or et al. 2002/0132793 September 2002 Epstein et al. 2005/0101582 May 2005 Lyons et al. 2005/0192290 September 2005 Melamed 2006/0183773 August 2006 Bar-Or et al. 2006/0189655 August 2006 Bar-Or et al. 851972 October 1960 WO 97/48685 December 1997 WO 99/16439 April 1999 WO 99/36403 July 1999 WO 00/59880 October 2000 WO 00/74680 December 2000 WO 01/30337 May 2001 WO 01/68053 September 2001 WO 03/037247 May 2003 WO 2004/043480 May 2004 WO 2004/058289 July 2004 WO 2005/000203 January 2005 |
| Other References: | Auerbach “Angiogenesis Assays: A Critical Overview” Clinical Chemistry 49:132-40 (2003). cited by examiner Trisha Gura “Cancer Models: Systems for Identifying New Drugs Are Often Faulty” Science Nov. 7, 1997: vol. 278. No. 5340, pp. 1041-1042. cited by examiner Johnson, et. al. “Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.” British Journal of Cancer 2001, 84, 1424-1431. cited by examiner Damia “Contemporary pre-clinical development of anticancer agents—What are the optimal preclinical models?” European Journal of Cancer 2009, 45, 2768-2781. cited by examiner Sharma “Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents” Nature Reviews Cancer Apr. 2010, vol. 10, 241-253. cited by examiner Ocana, A. “Preclinical development of molecular targeted agents for cancer” Nat. Rev. Clin. Oncol. 2011, 8, 200-209. cited by examiner Online “http://dtp.nci.nih.gov/services/nci60data/onedose/759278” accessed Apr. 9, 2015. cited by examiner Online “http://dtp.nci.nih.gov/branches/btb/onedose—interp.html” accessed Apr. 9, 2015. cited by examiner Online “http://dtp.nci.nih.gov/services/nci60data/onedose/125973” accessed Apr. 9, 2015. cited by examiner Online “http://dtp.nci.nih.gov/docs/misc/common—files/submit—compounds.html” accessed Apr. 9, 2015. cited by examiner Wilhelm “Regorafenib (Bay 73/4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity” Int. J. Cancer 2011, 129, 245-255. cited by examiner “inteliHealth: Multiple Sclerosis,” available on the World Wide Web at http://www.intelihealth.com/IH/iht1H/WSIHW000/9339/10372.html, downloaded on May 7, 2006. cited by applicant Auci et al. “Methylphenidate and the immune system,” J Am Acad Child Adolcesc Psychiatry 1997, 36(8): 1015-1016. cited by applicant Breitbart et al., “A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease”, Arch Inern Med 2001, 161(3): 411-20, Abstract only, PubMed ID: 11176767. cited by applicant Bruera et al., Patient-Controlled Methylphenidate for the Management of Fatigue in Patients With Advanced Cancer: A Preliminary Report, Journal of Oncology, vol. 21, No. 23, Dec. 2003, pp. 4439-4443. cited by applicant Challman et al., “Methylphenidate: its pharmacology and uses”, Mayo Clin Proc 2000, 75: 711-721. cited by applicant Cruse et al., Illustrated Dictionary of Immunology (2nd edition, Taylor & Francis Group, CRC Press LLC, 2003), p. 475. cited by applicant Davies et al., “Synthesis of Methylphenidate Analogues and their Binding Affinities at Dopamine and Serotonin Transport Sites”, Bioorganic & Medicinal Chemistry Letters, 2004, vol. 14, pp. 1799-1802. cited by applicant Deutsch et al., “Synthesis and pharmacology of potential cocaine antagonists. 2. Structure—activity relationship studies of aromatic ring-substituted methylphenidate analogs,”, J Med Chem 1996, vol. 39, pp. 1201-1209. cited by applicant Meltzer et al., “The synthesis of bivalent 2β-carbomethoxy-3β-(3,4-dichloropheny1)-8- heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters,” Bioorganic and Medicinal Chemistry, Feb. 15, 2008, vol. 16, pp. 1832-1841. cited by applicant Martin et al., “Do Structurally Similar Molecules Have Similar Biological Activity?” Journal of Medicinal Chemistry, 2002, vol. 45, pp. 4350-4358. cited by applicant Dorwald, Side Reactions in Organic Synthesis:A Guide to Successful Synthesis Design, Wiley-VCH, copyright May 5, 2005, p. IX of Preface, pp. 1-15. cited by applicant Dunnick et al., “Decreased incidence of spontaneous mammary gland neoplasms in female F344 rats treated with amphetamine, methylphenidate, or codence”, Cancer Ltt 1996, 102(1-2): 77-83; Erratum in Cancer Lett 1996 105(1): 121-122, Abstract only, PubMed ID:8603383. cited by applicant Dunnick et al., “Decreased incidence of spontaneous mammary gland neoplasms in female F344 rats treated with amphetamine, methylphenidate, or codeine,” Cancer Letters, 1996, vol. 102(1-2), pp. 77-83. cited by applicant Dunnick et al., “Experimental studies on long-term effects of methylphenidate hydrochloride,” Toxicology 1995, 103(2): 77-84 Abstract only, PubMed ID: 8545847. cited by applicant Gatley et al., “Affinities of Methylphenidate derivative for dopamine, norepinephrine and seotonin transporters,” Life Sciences 1996, 58(12): 231-239. cited by applicant Happe, “Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management”, Drugs 2003, 63(24): 2725-2737 Abstract only, PubMed ID 14664652. cited by applicant Haran “Beyond just tired: figuring out MS-related fatigue”, available on the Worldwide Web at http://www.understandingsms.com/ms/articles/ms—beyondtired.asp, downloaded on May 7, 2006. cited by applicant Krim, Lori, Thesis (Ph.D. in Chemistry) (2001), University of Pennsylvania, Chemistry Library Reading Room (Call No. QD001 2001.K92), University Microfilms Order No. 3031684, ISBN 0493-44179-4, 762 pages. cited by applicant Krupp et al., “Fatigue in multiple sclerosis,” Curr Neurol Neurosci Rep, 2001, vol. 1(3), pp. 294-298. cited by applicant Leonard et al., “Methylphenidate: a review of its neuropharmacological, neuropsycological and adverse clinical effects,” Human Psychopharmacol Clin Exp 2004, 19:151-180. cited by applicant Natl Toxicol Program Tech Rep Ser, “NTP toxicology and carcinogenesis studies of methylphenidate hydrochloride (CAS No. 298-59-9) in F344/N rats and B6C3F1 mice (feed studies),” 1995, 439:1-299 Abstract only, PubMed ID 12595924. cited by applicant Pan et al., “Binding of bromine-substituted analogs of methylphenidate to monoamine transporters,” Euro J Pharmacol 1994, 264:177-182. cited by applicant Patrick et al., “Synthesis and pharmacology of hydroxylated metabolites of methylphenidate,” J Med Chem 1981, 24(1): 1237-1240. cited by applicant Ritalin, available on the World Wide Web at http://ms.about.com/od/treatment/a/Ritalin.htm, downloaded on May 7, 2006. cited by applicant Rozans et al., “Palliative Uses of Methylphenidate in Pateints With Cancer: A Review”, J. Clin. Oncology, Jan. 1, 2002, vol. 20, No. 1, pp. 335-339. cited by applicant Teo et al., “D-methylphenidate is non-genotoxic in in vitro and in vivo assays,” Mutat Res 2003, 537(1): 67-79 Abstract only, PubMed ID 12742508. cited by applicant Thai et al, “Asymmetric synthesis and pharmacology of methylphenidate and its para-substituted derivatives”, J Med Chem 1998, 41: 591-601. cited by applicant Thai et al., “Comparative pharmacokinetics and tissue distribution of the d-enantiomers of para-substituted methylphenidate analogs,” Drug Metabolism and Disposition 1999, 27(6): 645-650. cited by applicant Vargas et al., “Neuroglial activation and neuroinflammation in the brain of patients with autism”, Annal Neurol, Early View (Articles online in advance of print), Wiley InterScience::Article Full Text HTML, available on the World Wide Web at http://www3.interscience.wile.com/cgi-bin/fulltext/109793289/main.html,ftx—abs, downloaded on Nov. 15, 2004. cited by applicant Vigano et al., “Methylphenidate for the management of somatization in terminal cancer patients,” J Pain Symptom Manage 1995, 10(2): 167-170 Abstract only, PubMed ID 7730689. cited by applicant Wayment et al., “Effects on methylphenidate analogues on phenethylamine substrates for the striatal dopamine transporter: potential as amphetamine antagonists?” J Neurochem 1999, 72(3): 1266-1274 Abstract only, PubMed ID 10037500. cited by applicant Search Report for International (PCT) Patent Application No. PCT/US2006/002008, mailed Sep. 21, 2006. cited by applicant Written Opinion for International (PCT) Patent Application No. PCT/US2006/002008, mailed Sep. 21, 2006. cited by applicant International Preliminary Report on Patentability for International (PCT) Patent Application No. PCT/US2006/002008, mailed Aug. 2, 2007. cited by applicant Glavin et al. “Effects of Dopamine Agonists and Antagonists on Gastric Acid Secretion and Stress Responses in Rats.” Life Sciences, 1987, vol. 41 No. 11, p. 1397-1408. cited by applicant Marek “Psychotropic drugs and inflammatory reaction (III): Effects of single and repeated administration of psychotropic drugs on the bentonite oedema of the rat paw.”Activas Nervosa Superior, 1985, vol. 27, No. 1, p. 21-22. cited by applicant Schiller et al. “Methlyphenidate Hydrochloride (Ritalin) in Obstructive Pulmonary Disease.” Jour Allergy, 1958, vol. 29, No. 2, p. 160-164. cited by applicant “A to Z List of Cancers: Y,” National Cancer Institute, 2014 [retrieved on Jan. 13, 2014], 1 pages, Retrieved from: www.cancer.gov/cancertopics/types/alphalist/y. cited by applicant Beger et al, “Treatment of Pancreatic Cancer: Challenge of the Facts,” World Journal of Surgery, 2003, vol. 27, No. 10, pp. 1075-1084. cited by applicant Braun-Moscovici et al., “Stem cell therapy in scleroderma,” Current Opinion in Rheumatology, 2002, vol. 14, Iss.6, pp. 711-716. cited by applicant Chabner et al., “Chemotherapy and the war on cancer,” Nature Reviews Cancer, 2005, vol. 5, Iss. 1, pp. 65-72. cited by applicant Chou et al., “Structure—Activity Relationships of Substituted Benzothiophene-anthranilamide Factor Xa Inhibitors,” Bioorganic & Medicinal Chemistry Letters, 2003, vol. 13. Iss. 3, pp. 507-511. cited by applicant Cole et al., “Potential Tumor-Selective Nitroimidazolylmethyluracil Prodrug Derivatives: Inhibitors of the Angiogenic Enzyme Thymidine Phosphorylase,” Journal of Medicinal Chemistry, 2003, vol. 46, Iss. 2, pp. 207-209. cited by applicant Fisher et al., “The epidemiology of non-Hodgkin's lymphoma,” Oncogene, 2004, vol. 23, Iss. 38, pp. 6524-6534. cited by applicant Leaf, “The War on Cancer,” Fortune, Mar. 9, 2004, 13 pages. cited by applicant Schwartzbaum et al., “Epidemiology and molecular pathology of glioma,” Nature Clinical Practice Neurology, 2006, vol. 2 , No. 9, pp. 494-503. cited by applicant Swigris et al., “Idiopathic Pulmonary Fibrosis: Challenges and Opportunities for the Clinician and Investigator,” Chest, 2005, vol. 127, Iss. 1, pp. 275-283. cited by applicant Zhu et al., “Phosphate Prodrugs of PD154075,” Bioorganic & Medicinal Chemistry Letters, 2000, vol. 10, Iss. 10, pp. 1121-1124. cited by applicant |
| Primary Examiner: | O'Dell, David K |
| Attorney, Agent or Firm: | Sheridan Ross P.C. |
| Accession Number: | edspgr.09463187 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|